OncoBytes Adaptive Learning Pathways: Personalizing Treatment Plans to Optimize Adjuvant Therapy in Early-Stage HR+/HER2– Breast Cancer

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Joyce O’Shaughnessy, MD; Virginia Kaklamani, MD, DSc; and Seth A. Wander, MD, PhD; discuss real-world insights into tailoring adjuvant therapy regimens in hormone receptor–positive/HER2-negative (HR+/HER2–) early breast cancer (eBC).

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Assess risk factors for recurrence in patients with HR+/HER2– eBC
• Evaluate the role of genomic assays and clinical tools to assess recurrence risk in HR+/HER2– eBC
• Analyze the latest clinical trial data related to the use of adjuvant systemic therapies for high-risk, HR+/HER2– eBC
• Develop personalized treatment plans for adjuvant systemic therapy in patients with high-risk HR+/HER2– eBC
• Apply evidence-based strategies to mitigate and manage treatment-related adverse effects in patients receiving systemic adjuvant therapy for HR+/HER2– eBC

Acknowledgment of Educational Grant Support

This activity is supported by educational grants from AstraZeneca Pharmaceuticals and Merck Sharp & Dohme LLC.

Chair:

Joyce O’Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Director, Breast Cancer Research Program
Texas Oncology
US Oncology
Dallas, TX

Disclosures: Consultant: AbbVie, Agendia, Amgen, Aptitude Health, AstraZeneca, BioNTech, Byondis, Carrick Therapeutics, Daiichi Sankyo, DAVA Oncology, Eisai, Eli Lilly and Company, Fishawack Health, G1 Therapeutics, Genentech, Genzyme, Gilead Sciences, GSK, Loxo Oncology, Merck, Novartis, Ontada, Pfizer, Pierre Fabre, Puma Biotechnology, Roche, Samsung Bioepis, Sanofi, Seagen, Stemline Therapeutics, Taiho Oncology, Verily

Faculty:

Virginia Kaklamani, MD, DSc

Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
A.B. Alexander Distinguished Chair in Oncology
Leader, Breast Oncology Program
UT Health San Antonio MD Anderson Cancer Center
San Antonio, TX

Disclosures: Grant/Research Support: Eisai; Consultant: AstraZeneca, Genentech, Gilead, Lilly, Menarini, Pfizer; Speaker: AstraZeneca, Daiichi Sankyo, Gilead

Seth A. Wander, MD, PhD

Assistant Professor of Medicine
Harvard Medical School
Medical Oncologist
Massachusetts General Hospital
Boston, MA

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Arvinas, AstraZeneca, Biovica, Boundless Bio, Celcuity, Delcath Systems, Eli Lilly, Foundation Medicine, Genentech, Gilead, Halda Therapeutics, Hologic, Novartis, Pfizer, Puma Biotechnology, Regor Therapeutics, Stemline/Menarini, Veracyte; Grant/Research Funding: Arvinas, Eli Lilly, Genentech, Nuvation Bio, Pfizer, Phoenix Molecular Designs, Puma Biotechnology, Regor Therapeutics, Sermonix, Stemline/Menarini

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member.

To learn more about this topic—including information on genomic assays to inform treatment decisions, defining high-risk disease, and clinical trial data on CDK4/6, immune checkpoint, and PARP inhibitors—go to https://www.gotoper.com/courses/oncobytes-adaptive-learning-pathways-personalizing-treatment-plans-to-optimize-adjuvant-therapy-in-early-stage-hrher2-breast-cancer.

Release Date

April 20, 2026

Expiration Date

April 20, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.